Clinical efficacy and cost-effectiveness of local hemostatic agents in upper gastrointestinal bleeding
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S379
DOI: 10.1055/s-0044-1783634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von J. A. Meier und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Upper gastrointestinal bleeding (UGIB) is the most common manifestation of gastrointestinal (GI) bleedings. In recent years, local hemostatic agents became more widely available and are associated with a high rate of successful immediate yet short-term hemostasis. However, the clinical efficacy on UGIB recurrence is unknown. This study aims to evaluate the clinical efficacy of bentonite and synthetic peptides on immediate endoscopic hemostasis and UGIB recurrence.
Methods
This is a retrospective monocenter study. All patients with UGIB receiving local hemostatic agents (bentonite or synthetic peptides) at a tertiary center between 2013 and 2023 were included in the study. The outcome was immediate endoscopic hemostasis and UGIB recurrence.
Results
A total of 274 patients were included in the study. 252 patients (92%) were treated with either bentonite or synthetic peptides, 8% received both substances. 185 patients (68%) were male with a median age of 65 (56 – 75) years. The most common locations of UGIB were gastric (34%) and duodenal (38%). 31 (11%) and 37 (14%) patients were under medication with antiplatelet agents and oral anticoagulants, respectively. 125 patients (45.6%) had one and 49 (17.9%) had more than one recurrent UGIB episodes. Synthetic peptides and bentonite were used in 39% and 53% of index UGIB. Furthermore, synthetic peptides and bentonite were used in 25% and 12% of recurrent UGIB. Immediate endoscopic hemostasis was similarly high between both agents for index UGIB (94% (synthetic peptides) vs. 92% (bentonite), p =0.65) and recurrent UGIB (100% (synthetic peptides) vs. 88% (bentonite), p =0.12). Synthetic peptides showed a trend towards lower rates of recurrent UGIB but without statistical significance (37% (synthetic peptides) vs. 62% (bentonite), p =0.10). There were no adverse events with both agents.
Conclusions
Both bentonite and synthetic peptides are safe and effective local hemostatic agents in the treatment of UGIB, achieving high rates of local hemostasis during index UGIB. Synthetic peptides showed a trend toward lower rates of recurrent UGIB episodes. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Meier, J. A., Sanoubara, F., Wenge, V. C., Kimmann, M., Groba, S. N. R., Weppelmann, F., Gödiker, J., Trebicka, J., & Praktiknjo, M. (2024). Clinical efficacy and cost-effectiveness of local hemostatic agents in upper gastrointestinal bleeding. Endoscopy, 56(S 02 S 02), S379. https://doi.org/10.1055/s-0044-1783634
Vancouver
Meier JA, Sanoubara F, Wenge VC, Kimmann M, Groba SNR, Weppelmann F, et al. Clinical efficacy and cost-effectiveness of local hemostatic agents in upper gastrointestinal bleeding. Endoscopy. 2024;56(S 02 S 02):S379. doi:10.1055/s-0044-1783634
BibTeX
@article{Meier2024,
author = {Meier, J. A. and Sanoubara, F. and Wenge, V. C. and Kimmann, M. and Groba, S. N. Reinartz and Weppelmann, F. and Gödiker, J. and Trebicka, J. and Praktiknjo, M.},
title = {Clinical efficacy and cost-effectiveness of local hemostatic agents in upper gastrointestinal bleeding},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S379},
doi = {10.1055/s-0044-1783634}
}
EUVIMED